MedTrace Logo

Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B

NCT03933384 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2026-05-14

No results posted yet for this study

Summary

To compare the efficacy and renal safety of tenofovir alafenamide (TAF) versus entecavir (ETV) in the chronic hepatitis B patients.

Conditions

Interventions

DRUG

Tenofovir alafenamide

Tenofovir alafenamide 25mg/tab once daily

DRUG

Entecavir

Entecavir 0.5mg/tab once daily

Sponsors & Collaborators

  • Taichung Veterans General Hospital

    lead OTHER

Principal Investigators

  • Teng-Yu Lee, MD, PhD · Taichung Veterans General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-19
Primary Completion
2027-12-31
Completion
2030-12-31
FDA Drug
Yes

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03933384 on ClinicalTrials.gov